John Power
Founder and CEO, Aerogen
WHY THE US
Aerogen’s decision to establish and grow its presence in the United States is deeply connected to our purpose of improving patient outcomes through innovation in acute care aerosol drug delivery. As the world leader in this field, with more than 25 years of expertise and a global footprint across 80+ countries, Aerogen has supported over 30 million patients worldwide. The US is central to this impact and having operations on the ground allows Aerogen to work directly with the clinicians, hospital systems, and industry partners who rely on our technology every day. Today, Aerogen supports more than 3,100 North American customers and is connected in 95% of the top 1,000 hospitals in the US, including 81% of children’s hospitals and 94% of the top short-term acute hospitals. In 2025 alone, more than 2.1 million patients in North America benefited from Aerogen technology.
Aerogen’s long-term commitment to the US is reflected in our investment of approximately $270 million since 2007 supporting clinical research, medical affairs and commercial operations out of our facilities in Chicago, North Carolina and San Mateo CA. Backed by full FDA, CE, and worldwide approvals, over 300 peer-reviewed clinical studies, and more than 700 international patents, Aerogen continues to translate evidence-based aerosol drug delivery innovation in our field into real-world care at scale.
A key driver of our US future is Aerogen Pharma, which is pioneering the next generation of inhaled therapeutics for acute and critical care. The lead program of our US clinical research team is an aerosol surfactant delivery system for treatment of premature infants suffering acute respiratory distress. This potentially groundbreaking program, currently in its final trials, is looking to substantially reduce the need for intubation of these most vulnerable of patients. Further collaboration in this field with Bill & Melinda Gates Foundation has led to the development of a program to potentially bring the benefit of inhaled surfactant for premature infants beyond hospitals in developed markets to vulnerable patients globally.
In 2025 Aerogen was proud to be the first company in the world to be presented with ten consecutive Zenith Awards by the American Association of Respiratory Care reflecting our ongoing commitment to providing world-leading healthcare solutions to our US partners.